The European Commission (EC) has approved AstraZeneca’s Bydureon BCise, a new weekly formulation of established GLP-1 diabetes drug with the added benefit of glucose reduct
Novo Nordisk is making the case for its diabetes pill, which it hopes will allow it to fight off competition from rivals in a highly competitive market.
Two diabetes drugs, Lilly and Boehringer Ingelheim’s (BI) Jardiance and Novo Nordisk’s Victoza, have shown they can go beyond lowering blood sugar, and actually save lives and cut heart attacks
A report issued by the office of US Senator Bernie Sanders has claimed that the high prices being charged for new GLP-1 agonist-based obesity therapies like Novo Nordisk’s
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.